Younger Kidney Cancer Patients on VEGF Inhibitors at Elevated Risk for Hypertension
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 26, 2023 -- Hypertension during treatment is common among adolescents and young adults (AYAs) being treated with vascular endothelial growth factor (VEGF) inhibitors for renal cancer, according to a study published online July 5 in the Journal of the National Comprehensive Cancer Network.
Wendy J. Bottinor, M.D., from Virginia Commonwealth University in Richmond, and colleagues assessed the incidence and predictors of left ventricular systolic dysfunction (LVSD) and hypertension among AYAs receiving VEGF inhibition. The analysis included 1,572 participants (103 AYAs aged 18 to 39 years) with nonmetastatic, high-risk renal cell cancer who were randomly assigned to sunitinib, sorafenib, or placebo.
The researchers found that during 54 weeks of treatment, the incidence of LVSD was not significantly different among AYAs (3 percent) versus non-AYAs (2 percent). Among AYAs, the incidence of hypertension was significantly lower versus non-AYAs in the placebo arm (8 versus 46 percent). The incidence of hypertension was 29 percent for AYAs versus 47 percent for non-AYAs in the sunitinib group and 54 versus 63 percent in the sorafenib group. A lower risk for hypertension was seen with AYA status (odds ratio, 0.48) and female sex (odds ratio, 0.74).
"The large number of AYAs who had high blood pressure during treatment with sunitinib or sorafenib suggests that even individuals without identifiable pre-existing factors -- such as older age, obesity, and male gender -- are also at significant risk for hypertension from these drugs," Bottinor said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
HTN, Albuminuria Risks No Worse for Kidney Donors Versus Nondonors
THURSDAY, May 30, 2024 -- Living kidney donors and nondonors have similar risks for hypertension and albuminuria, according to a study published online May 23 in the Journal of...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.